Assertio Therapeutics Inc logo

ASRT - Assertio Therapeutics Inc Share Price

$1.24 0.0  2.5%

Last Trade - 17/01/20

Sector
Healthcare
Size
Small Cap
Market Cap £74.7m
Enterprise Value £312.8m
Revenue £162.8m
Position in Universe 4289th / 6416
Bullish
Bearish
Unlock ASRT Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ASRT Revenue Unlock ASRT Revenue

Net Income

ASRT Net Income Unlock ASRT Revenue

Normalised EPS

ASRT Normalised EPS Unlock ASRT Revenue

PE Ratio Range

ASRT PE Ratio Range Unlock ASRT Revenue

Dividend Yield Range

ASRT Dividend Yield Range Unlock ASRT Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ASRT EPS Forecasts Unlock ASRT Revenue
Profile Summary

Assertio Therapeutics, Inc. is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), Cambia (diclofenac potassium for oral solution), Xartemis XR and Zipsor (diclofenac potassium). Its NUCYNTA ER (tapentadol extended release tablets) is a product for the management of pain severe enough to require daily long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults, and its NUCYNTA (tapentadol) is a product for the management of moderate to severe acute pain in adults. Its Gralise (gabapentin) is a once-daily product for the management of postherpetic neuralgia (PHN). Its Cambia (diclofenac potassium for oral solution) is a product for the acute treatment of migraine attacks.

Directors
Last Annual December 31st, 2018
Last Interim September 30th, 2019
Incorporated July 18, 2018
Public Since April 15, 2014
No. of Shareholders: 19
No. of Employees: 116
Sector Healthcare
Industry Pharmaceuticals
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 80,681,036
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ASRT Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ASRT
Upcoming Events for ASRT
Similar to ASRT
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.